0000921895-23-001765.txt : 20230731
0000921895-23-001765.hdr.sgml : 20230731
20230731193808
ACCESSION NUMBER: 0000921895-23-001765
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230726
FILED AS OF DATE: 20230731
DATE AS OF CHANGE: 20230731
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Ben-Tzvi Avraham
CENTRAL INDEX KEY: 0001944721
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-13341
FILM NUMBER: 231129094
MAIL ADDRESS:
STREET 1: 44 ZAYT SHEMEN ST.
STREET 2: FLAT 4
CITY: EFRAT
STATE: L3
ZIP: 9045544
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: TITAN PHARMACEUTICALS INC
CENTRAL INDEX KEY: 0000910267
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 943171940
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 400 OYSTER POINT BLVD
STREET 2: SUITE 505
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94080
BUSINESS PHONE: 6502444990
MAIL ADDRESS:
STREET 1: 400 OYSTER POINT BLVD
STREET 2: SUITE 505
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94080
4
1
form413531ben_07282023.xml
OWNERSHIP DOCUMENT
X0508
4
2023-07-26
0
0000910267
TITAN PHARMACEUTICALS INC
TTNP
0001944721
Ben-Tzvi Avraham
44 ZAYT SHEMEN ST.
FLAT 4
EFRAT
L3
9045544
ISRAEL
1
0
0
0
0
Common Stock
2023-07-26
4
A
0
50000
0
A
50000
D
Option to Purchase Common Stock
1.52
2023-06-29
4
A
0
25000
0
A
2032-08-15
Common Stock
25000
25000
D
Option to Purchase Common Stock
1.31
2023-06-29
4
A
0
100000
0
A
2032-09-15
Common Stock
100000
100000
D
The shares reported in this transaction represent Unrestricted Stock Awards pursuant to the Issuer's Fourth Amended and Restated 2015 Omnibus Equity Incentive Plan that vested immediately on the date of grant.
The options were approved by the Issuer's Board of Directors on August 15, 2022. The options were conditioned on the approval by the Issuer's stockholders of an increase in the number of shares available for issuance under the 2015 Omnibus Equity Incentive Plan, which approval occurred on June 29, 2023. The exercise price of the options is equal to the closing price of the Issuer's common stock on August 15, 2022.
The options were approved by the Issuer's Board of Directors on September 15, 2022. The options were conditioned on the approval by the Issuer's stockholders of an increase in the number of shares available for issuance under the 2015 Omnibus Equity Incentive Plan, which approval occurred on June 29, 2023. The exercise price of the options is equal to the closing price of the Issuer's common stock on September 15, 2022.
/s/ Avraham Ben-Tzvi
2023-07-31